Intelligence / Healthtech / PMA Approvals / Roche
Approvalsdevice change approved (PMA)4 Nov 2026
Roche
4 Nov 2026: Device change approved (PMA) · Roche cobas® EGFR Mutation Test, v2.0. Recorded in the openFDA device PMA data.
- Decided
- 4 Nov 2026
- Device
- Roche cobas® EGFR Mutation Test, v2.0
- Specialty
- Pathology
- Type
- Supplement (Special (Immediate Track))
- Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Reference
- P120019 S045
- Location
- Peasanton, CA
What this signal means
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Roche
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
More in Pathology
PMA Approvals
4 NovRoche Molecular Systems, INC.device change approved (PMA) · Roche cobas® KRAS Mutation TestApprovals4 NovRoche Molecular Systems, INC.device change approved (PMA) · Roche cobas® BRAF V600 Mutation TestApprovals23 OctVentana Medical Systems, INC. (Roche Tissue Diagnostics)device change approved (PMA) · VENTANA MET (SP44) RxDx AssayApprovals8 OctVentana Medical Systemsdevice change approved (PMA) · VENTANA MMR RxDx PanelApprovals8 OctVentana Medical Systems, INC. (Roche Tissue Diagnostics)device change approved (PMA) · VENTANA MMR RxDx PanelApprovals18 SeptGuardant Health, INC.device change approved (PMA) · Guardant360 CDxApprovals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.